FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955202454> ?p ?o ?g. }

• W2955202454 endingPage "CT053" @default.
• W2955202454 startingPage "CT053" @default.
• W2955202454 abstract "Abstract T-DM1, an antibody drug conjugate (ADC), has been approved by FDA for patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane. DM1 is released because it is connected to the linker of T-DM1 by a thio-ether bond, which can be broken via retro-Michael addition. To improve the antibody-drug stability, we created an anti-HER2 ADC (BAT8001) which used a novel uncleavable linker to connect trastuzumab and a payload of maytansine derivative. BAT8001 exhibits similar level of potency against proliferation of HER2-overexpressed cells as T-DM1 and demonstrates strong inhibition activity on tumor growth in both cell-line and patient-derived xenograft models. Pharmacokinetics (PK) study in monkey reveals BAT8001 has similar level of exposure, half-life, and Cmax as T-DM1. BAT8001 Ph1 clinical trial in patients with HER2+ late-stage breast cancer recently was completed. The clinical study used standard “3+3” multiple-dose escalation method, evaluated BAT8001 safety, PK and explored the efficacy. Twenty-nine subjects were randomized and 27 subjects received the treatment with escalated dose 1.2mg/kg, 2.4mg/kg,3.6mg/kg, 4.8mg/kg and 6.0mg/kg. Two subjects died during the screening time without treatment due to disease progression. Nineteen (79.2%) subjects completed at least 4-cycle treatment. The PK parameter (Cmax and AUC(0-t)) values demonstrated dose-dependent linear relationship. In the safety evaluation, the incidences of AE and AE with CTCAE &gt;=3 increased when dose escalated. The platelet count decrease and AST elevation were found to be the most common and severe AEs. Three subjects had serious adverse events (SAE) of bone destruction which were considered to be not investigated-drug related by the PI. Among those 3 subjects, 2 subjects withdrew from the study due to the SAE and 1 subject continued the treatment. The preliminary efficacy assessment after 10 months treatment found that 1 (3.7%) patient exhibited the complete response (CR), 5 (18.5%) patients exhibited the partial responses (PR), and 5(18.5%) patients exhibited the stable diseases. Based on the information above, the dose of 3.6mg/kg achieved target drug exposure and was found to be the effective and well-tolerated, which was selected to be the dose in the confirmatory clinical trial. Currently, a Phase 3, multicenter, randomized, open-label, controlled trial evaluating the efficacy and safety of BAT8001 has been initiated in patients with HER2+ metastatic breast cancer who previously received trastuzumab separately or in combination with taxanes. The trial is designed to compare BAT8001 versus lapatinib combined with capecitabine which is 2nd-line standard of care for metastatic breast cancer patients in China. This Phase 3 trial plans to recruit approximately 410 patients and by Jan 2019 more than 130 patients have received the treatment of BAT8001. The BAT8001 benefit-risk profile continues to support further development and the clinical results will be revealed by early 2020. Citation Format: Shusen Wang, Fei Xu, Ruoxi Hong, Wen Xia, Jin-Chen Yu, Weijia Tang, Jin Wei, ShuQiang Song, Zhaohe Wang, Li Zhang, Shengfeng Li. BAT8001, a potent anti-HER2 antibody drug conjugate with a novel uncleavable linker to reduce toxicity for patients with HER2-positive tumor [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr CT053." @default.
• W2955202454 created "2019-07-12" @default.
• W2955202454 creator A5025674859 @default.
• W2955202454 creator A5030507461 @default.
• W2955202454 creator A5031085527 @default.
• W2955202454 creator A5052040061 @default.
• W2955202454 creator A5055751859 @default.
• W2955202454 creator A5057736963 @default.
• W2955202454 creator A5057751836 @default.
• W2955202454 creator A5063918608 @default.
• W2955202454 creator A5066716873 @default.
• W2955202454 creator A5080472057 @default.
• W2955202454 creator A5083140640 @default.
• W2955202454 date "2019-07-01" @default.
• W2955202454 modified "2023-09-26" @default.
• W2955202454 title "Abstract CT053: BAT8001, a potent anti-HER2 antibody drug conjugate with a novel uncleavable linker to reduce toxicity for patients with HER2-positive tumor" @default.
• W2955202454 doi "https://doi.org/10.1158/1538-7445.am2019-ct053" @default.
• W2955202454 hasPublicationYear "2019" @default.
• W2955202454 type Work @default.
• W2955202454 sameAs 2955202454 @default.
• W2955202454 citedByCount "4" @default.
• W2955202454 countsByYear W29552024542020 @default.
• W2955202454 countsByYear W29552024542022 @default.
• W2955202454 crossrefType "journal-article" @default.
• W2955202454 hasAuthorship W2955202454A5025674859 @default.
• W2955202454 hasAuthorship W2955202454A5030507461 @default.
• W2955202454 hasAuthorship W2955202454A5031085527 @default.
• W2955202454 hasAuthorship W2955202454A5052040061 @default.
• W2955202454 hasAuthorship W2955202454A5055751859 @default.
• W2955202454 hasAuthorship W2955202454A5057736963 @default.
• W2955202454 hasAuthorship W2955202454A5057751836 @default.
• W2955202454 hasAuthorship W2955202454A5063918608 @default.
• W2955202454 hasAuthorship W2955202454A5066716873 @default.
• W2955202454 hasAuthorship W2955202454A5080472057 @default.
• W2955202454 hasAuthorship W2955202454A5083140640 @default.
• W2955202454 hasConcept C112705442 @default.
• W2955202454 hasConcept C121608353 @default.
• W2955202454 hasConcept C126322002 @default.
• W2955202454 hasConcept C143998085 @default.
• W2955202454 hasConcept C159654299 @default.
• W2955202454 hasConcept C185592680 @default.
• W2955202454 hasConcept C202751555 @default.
• W2955202454 hasConcept C203014093 @default.
• W2955202454 hasConcept C22979827 @default.
• W2955202454 hasConcept C2775930923 @default.
• W2955202454 hasConcept C2777325958 @default.
• W2955202454 hasConcept C2777511904 @default.
• W2955202454 hasConcept C2779786085 @default.
• W2955202454 hasConcept C29730261 @default.
• W2955202454 hasConcept C530470458 @default.
• W2955202454 hasConcept C542903549 @default.
• W2955202454 hasConcept C55493867 @default.
• W2955202454 hasConcept C57992300 @default.
• W2955202454 hasConcept C71924100 @default.
• W2955202454 hasConcept C98274493 @default.
• W2955202454 hasConceptScore W2955202454C112705442 @default.
• W2955202454 hasConceptScore W2955202454C121608353 @default.
• W2955202454 hasConceptScore W2955202454C126322002 @default.
• W2955202454 hasConceptScore W2955202454C143998085 @default.
• W2955202454 hasConceptScore W2955202454C159654299 @default.
• W2955202454 hasConceptScore W2955202454C185592680 @default.
• W2955202454 hasConceptScore W2955202454C202751555 @default.
• W2955202454 hasConceptScore W2955202454C203014093 @default.
• W2955202454 hasConceptScore W2955202454C22979827 @default.
• W2955202454 hasConceptScore W2955202454C2775930923 @default.
• W2955202454 hasConceptScore W2955202454C2777325958 @default.
• W2955202454 hasConceptScore W2955202454C2777511904 @default.
• W2955202454 hasConceptScore W2955202454C2779786085 @default.
• W2955202454 hasConceptScore W2955202454C29730261 @default.
• W2955202454 hasConceptScore W2955202454C530470458 @default.
• W2955202454 hasConceptScore W2955202454C542903549 @default.
• W2955202454 hasConceptScore W2955202454C55493867 @default.
• W2955202454 hasConceptScore W2955202454C57992300 @default.
• W2955202454 hasConceptScore W2955202454C71924100 @default.
• W2955202454 hasConceptScore W2955202454C98274493 @default.
• W2955202454 hasIssue "13_Supplement" @default.
• W2955202454 hasLocation W29552024541 @default.
• W2955202454 hasOpenAccess W2955202454 @default.
• W2955202454 hasPrimaryLocation W29552024541 @default.
• W2955202454 hasRelatedWork W1971716849 @default.
• W2955202454 hasRelatedWork W1995439679 @default.
• W2955202454 hasRelatedWork W2104688192 @default.
• W2955202454 hasRelatedWork W2163622510 @default.
• W2955202454 hasRelatedWork W2941237838 @default.
• W2955202454 hasRelatedWork W3015966475 @default.
• W2955202454 hasRelatedWork W316677534 @default.
• W2955202454 hasRelatedWork W4255120648 @default.
• W2955202454 hasRelatedWork W4300176258 @default.
• W2955202454 hasRelatedWork W4306758939 @default.
• W2955202454 hasVolume "79" @default.
• W2955202454 isParatext "false" @default.
• W2955202454 isRetracted "false" @default.
• W2955202454 magId "2955202454" @default.
• W2955202454 workType "article" @default.